fda warning letters compounded semaglutide november 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s FDA Warns on Certain Forms

Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P

Rabinkov et al., 2000 )

Pre-restart assessment should include: Review of the reason for discontinuation and whether it has been adequately addressed Current weight and glycemic status (if diabetic) Assessment of gastrointestinal symptoms and any contraindications Medication reconciliation to identify potential drug interactions For patients taking insulin or sulfonylureas, consider dose reductions to prevent hypoglycemia For women of childbearing potential using oral contraceptives, recommend backup contraception for 4 weeks after restarting and after each dose increase Discussion of realistic expectations and commitment to continued treatment Patient counseling is essential

Many patients told us that the decision to suspend their injections and switch to oral B12 tablets during the pandemic ruined their lives